Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focused on developing innovative drugs and has a strong emphasis on self-sustaining capabilities in drug development [2][4]. - The company aims to enhance the pharmaceutical level in China through original technology capabilities [4]. Group 2: Research and Development Strategy - The company is strategically positioning its biopharmaceutical pipeline by focusing on clinically validated targets to improve success rates and reduce risks [5]. - Kanghong is also exploring new mechanisms and molecules, while balancing the development of biosimilars to maintain competitiveness [5][6]. Group 3: Product Development Focus - Kanghong is actively working on products for the treatment of myopia and has ongoing research in this area [5]. - The company is investing in gene therapy, with plans to develop a platform that focuses on major diseases with significant medical needs [6]. Group 4: Team and Innovation Management - The company emphasizes a balanced approach to innovation, assessing both high-risk and low-risk projects in its R&D pipeline [6]. - Kanghong aims to build a capable team that can realize the company's vision, leveraging the experience of its leadership to train team members [6].
康弘药业(002773) - 2020年9月15日投资者关系活动记录表